S.Amdt. 2111

SA 2111. Ms. KLOBUCHAR submitted an amendment intended to be proposed
by her to the concurrent resolution H. Con. Res. 14, establishing the
congressional budget for the United States Government for fiscal year
2025 and setting forth the appropriate budgetary levels for fiscal
years 2026 through 2034; which was ordered to lie on the table; as
follows:

At the appropriate place, insert the following:

SEC. ___. DEFICIT-NEUTRAL RESERVE FUND RELATING TO RESEARCH
AND PRODUCT REVIEWS BY THE FOOD AND DRUG
ADMINISTRATION FOR RARE DISEASES.

The Chairman of the Committee on the Budget of the Senate
may revise the allocations of a committee or committees,
aggregates, and other appropriate levels in this resolution,
and make adjustments to the pay-as-you-go ledger, for one or
more bills, joint resolutions, amendments, amendments between
the Houses, motions, or conference reports relating to
research and product reviews by the Food and Drug
Administration for rare diseases, which may include efforts
to accelerate the development and approval of treatments,
improvements in regulatory science, or support for research
on innovative therapies, by the amounts provided in such
legislation for those purposes, provided that such
legislation would not increase the deficit over the period of
the total of fiscal years 2025 through 2034.
______